BMS
BMS Submits Breyanzi for European Approval as Second-Line Lymphoma Treatment
The CAR T-cell therapy is already approved in Europe as a third-line treatment for relapsed or refractory large B-cell lymphoma.
At ASCO, Biomarker Strategies Show Potential for Guiding Metastatic Pancreatic Cancer Treatment
Premium
Two studies presented Friday suggested that biomarker-selected approaches could improve patient outcomes on immunotherapy and targeted therapy.Â
Novartis' Kymriah Nabs FDA Approval in Refractory Follicular Lymphoma
The FDA based its decision on data from the ELARA trial, in which 68 percent of patients experienced a complete response to the CAR T-cell therapy.
BMS Shows Breyanzi Benefit in Stem Cell Transplant-Ineligible LBCL
The new data further support the benefit of the CAR T-cell therapy as a second-line option for refractory LBCL patients.Â
BMS's Opdivo, Yervoy Combo Fails to Improve Overall Survival Versus Chemo in Bladder Cancer Trial
While the Phase III trial didn't meet the primary overall survival endpoint in PD-L1-positive patients, BMS will continue to track other endpoints.
Mar 4, 2022